PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

A research team affiliated with UNIST has unveiled a novel approach to halt the progression of colorectal cancer by inducing ...

Immune checkpoint inhibitors (ICIs) are a form of immunotherapy that activates anti-tumor immune cells. In the context of ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have uncovered how targeted lung cancer drugs alter the shape and behavior of a key ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. With an overall survival rate of around 13%, it’s also one of the deadliest cancers. One reason for this is that ...

National Institutes of Health (NIH) scientists and collaborators say they have discovered a new way in which RAS genes, commonly mutated in cancer, may drive tumor growth beyond their well-known role ...